DeutschNewstral
Article
bizjournals.com on 2017-10-10 16:34
Merck takes stake in small Cambridge rare disease biotech, lifting shares
Related news
- Cambridge biotech Acceleron to be acquired by Merck for $11.5Bbizjournals.com
Merck & Co Inc: Merck signs $3bn deal for Kate Bingham-backed eye disease biotechFinancial Times- Cambridge biotech startup grabs $65M to tackle liver diseasebizjournals.com
- Cambridge biotech with rare blood disease drug secures $59Mbizjournals.com
- Cambridge rare disease biotech Synageva to be acquired for $8.4Bbizjournals.com
- Cambridge biotech delivers coronavirus vaccinebizjournals.com
- G“Global Antivenom Market 2022-28 Top Players: CSL ,Merck ,BTG ,Pfizer ,Haffkine Bio-Pharmaceutical ,Rare Disease Therapeutics ,Flynn Pharma ,Vins Bioproducts ,Bharat Serums and Vaccines ,Serum Biotech ,MicroPharm ,”galleonnews.com
- The Petri Dish: Merck names Cambridge site leader, HotSpot inks $40M+ dealbizjournals.com
Portage Biotech in new partnership with Merckwestfaironline.com- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Cambridge biotech to return its PPP loanbizjournals.com
- Cambridge biotech relocates to West Coastbizjournals.com
- Cambridge biotech plans manufacturing hub in Marylandbizjournals.com
- Cambridge biotech Werewolf gets $72M funding roundbizjournals.com
- BMerck Closes Biggest Biotech Deal of the Year3 min readbarrons.com
- Merck snaps up preclinical Lexington biotech for up to $773Mbizjournals.com
- Merck drops $2.7B on 26-year-old Burlington biotechbizjournals.com
- Former Merck CEO Ken Frazier joins Cambridge venture capital firmbizjournals.com
- TCambridge brothers lifting Pope John Paul II boystennessean.com
- A requirement at this Cambridge biotech: Must love dogsbizjournals.com